Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06836050 · ClinicalTrials.gov registry record
IPV and Lung Compliance in Invasively Ventilated Children
A clinical trial of Pediatric Respiratory Diseases and Pediatric Acute Respiratory Distress Syndrome (PARDS), sponsored by Northwell Health.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT06836050: Recruiting study of Pediatric Respiratory Diseases and Pediatric Acute Respiratory Distress Syndrome (PARDS), sponsored by Northwell Health.
NCT06836050 is a study of Pediatric Respiratory Diseases and Pediatric Acute Respiratory Distress Syndrome (PARDS) that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 30 participants, below the 114-participant average among 3 other Pediatric Respiratory Diseases trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06836050, a study of Pediatric Respiratory Diseases and Pediatric Acute Respiratory Distress Syndrome (PARDS), is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to determine if Intrapulmonary Percussive Ventilation (IPV) improves lung compliance in children receiving conventional invasive mechanical ventilation. The main questions it aims to answer are: 1. Does IPV improve lung compliance 15 minutes after and 3 hours after receiving one treatment in a heterogeneous group of pediatric patients? 2. Does IPV improve lung compliance in patients with Pediatric Acute Respiratory Distress Syndrome (PARDS), and what is the degree of change compared to those without PARDS? 3. What is the effect of IPV on lung compliance according to PARDS severity (mild-moderate disease vs. severe disease). 4. What is the incidence of adverse effects of IPV? Participants will receive IPV because their medical team feels it will help their lung recovery and has already determined them to be safe candidates to receive this therapy, which is a standard airway clearance modality already routinely used in our PICU. Nothing additional will happen to participants as a result of this study. Enrolling in this study simply gives the study team permission to collect specific health information that identifies your child for research purposes, which may include results from medical tests found in their medical record and information from your child's bedside monitor and ventilator. This information will be collected before and after the IPV treatments to evaluate their response to the therapy.
Primary Outcome
A measurement calculated and obtained from the patient's ventilator, averaged over 1 minute.
Conditions Studied
Study Locations (1)
New York
- Cohen Children's Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-12 |
What NCT06836050 shows while recruiting
NCT06836050 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 114-participant average among 3 other Pediatric Respiratory Diseases trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Pediatric Respiratory Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT06836050 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06836050 about?
NCT06836050 is a clinical study titled "IPV and Lung Compliance in Invasively Ventilated Children". The goal of this observational study is to determine if Intrapulmonary Percussive Ventilation (IPV) improves lung compliance in children receiving conventional invasive mechanical ventilation. The main questions it aims to answer are: 1. Does IPV improve lung compliance 15 minutes after and 3 hours...
What is the current status of trial NCT06836050?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-01-13. Estimated completion is 2026-12.
What conditions does trial NCT06836050 study?
This clinical trial studies the following conditions: Pediatric Respiratory Diseases, Pediatric Acute Respiratory Distress Syndrome (PARDS), Lung Compliance.
Who is sponsoring clinical trial NCT06836050?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06836050 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Respiratory Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI